Prevalence of resistance to 11 antimicrobials among Campylobacter coill isolated from pigs on 80 grower-finisher farms in Ontario.
We carried out a cross-sectional study to investigate antimicrobial resistance patterns of Campylobacter coli isolated from Ontario grower-finisher pigs. From January to June 2004, 1200 samples were collected from 80 farms by obtaining a constant number (15) of fecal samples per farm. Susceptibility of the isolates to 11 antimicrobial drugs was determined by the agar-dilution technique. The overall prevalence of resistance to 1 or more antimicrobials among the isolates was 99.2%. High levels of resistance were observed for azithromycin, clindamycin, erythromycin, streptomycin, and tetracycline: 91.7%, 82.5%, 81.4%, 70.7%, and 63.7%, respectively. For sulfamethoxazole, ampicillin, and nalidixic acid, resistance was observed in 40.3%, 26.6%, and 22.7% of the isolates, respectively. Although at very low levels, resistance was observed for ciprofloxacin (a fluoroquinolone), chloramphenicol, and gentamicin: in 2.4%, 1.7%, and 0.2%, respectively. Many of the isolates (29.7%) were resistant to 5 antimicrobials, the most common being azithromycin, clindamycin, erythromycin, streptomycin, and tetracycline. Isolates from the same farm showed at least 5 patterns of resistance. Results from this study indicate high levels of resistance to the antimicrobial drugs most commonly used in the Canadian swine industry (macrolides, lincosamides, and tetracyclines) among C. coli isolated from grower-finisher pigs in Ontario. Macrolides and fluoroquinolones are the drugs most commonly used to treat severe human campylobacteriosis. Fortunately, at present, there is little resistance to fluoroquinolones among C. coli from pigs in Ontario.
Varela
Norma P
NP
Department of Population Medicine, Ontario Veterinary College, University of Guelph, Guelph, Ontario.
Friendship
Robert
R
Dewey
Cate
C
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002169:Campylobacter Infections / Q000188:drug therapy / Q000662:veterinary*; D017000:Campylobacter coli / Q000187:drug effects* / Q000302:isolation & purification; D015169:Colony Count, Microbial / Q000662:veterinary; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D005243:Feces / Q000382:microbiology; D008826:Microbial Sensitivity Tests / Q000662:veterinary; D009864:Ontario; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy*
D000900:Anti-Bacterial Agents
J Antimicrob Chemother. 2004 May;53(5):872-4
15028665
Antimicrob Agents Chemother. 2001 Jul;45(7):2054-9
11408222
Emerg Infect Dis. 2004 Jun;10(6):1102-9
15207064
J Clin Microbiol. 1984 Oct;20(4):636-40
6490850
J Hyg (Lond). 1985 Aug;95(1):15-21
4020108
J Clin Microbiol. 1987 Oct;25(10):2030-1
3667928
J Antimicrob Chemother. 1993 Dec;32(6):906-7
8144435
Science. 1994 Apr 15;264(5157):375-82
8153624
J Antimicrob Chemother. 1995 Dec;36(6):891-8
8821589
Antimicrob Agents Chemother. 1997 Oct;41(10):2244-50
9333055
Can Vet J. 1998 Feb;39(2):87-96
10051955
Prev Vet Med. 2005 Jul 12;69(3-4):189-202
15907569
Can J Vet Res. 2006 Apr;70(2):81-6
16639939
Antimicrob Agents Chemother. 2000 Feb;44(2):267-71
10639348
Mem Inst Oswaldo Cruz. 2000 Mar-Apr;95(2):247-9
10733748
Emerg Infect Dis. 2001 Jan-Feb;7(1):24-34
11266291
Emerg Infect Dis. 2001 May-Jun;7(3):489-90
11384547
Vet Microbiol. 2004 Jun 21;101(2):91-9
15172691